JBJosé Pedro Boléo-Tomé

José Pedro Boléo-Tomé

*This is an algorithmically generated author record based on publicly available information.

José Pedro Boléo-Tomé has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Rita Tavares Dias

    Hospital Pulido Valente, Portugal

    2 shared publications
  • Carlos Robalo Cordeiro

    Serviço de Pneumologia. Centro Hospitalar e Universitário de Coimbra. Coimbra. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Sociedade Europeia Respiratória. Lausanne. Suíça. Portugal

    2 shared publications
  • Cláudia Matos

    Lung Unit, The Champalimaud Center for the Unknown

    2 shared publications
  • David Peres

    Infection Control and Antimicrobial Resistance Unit, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal

    2 shared publications
  • Joana Isaac Teixeira

    Hospital Pulido Valente, Portugal

    2 shared publications
  • João Cardoso

    Pulmonology Department, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, EPE (CHLC), Lisbon, Portugal; Nova Medical School, Nova University, Lisbon, Portugal

    2 shared publications

Latest Publications

  • Open Access

    Association of acute COVID-19 severity and long COVID fatigue and quality of life: Prospective cohort multicenter observational study

    by Ligia Pires, Ana Marreiros, Cátia Saraiva, Cláudia Reis, Djamila Neves, Cláudia Guerreiro, José Boleo Tomé, Maria Inês Luz, Margarida Isabel Pereira, Ana Sofia Barroso, et al.

    Long COVID, or post-COVID-19 condition, is characterized by symptoms persisting beyond 12 weeks after severe acute respiratory syndrome coronavirus 2 infection, affecting individuals regardless of acute disease severity. Fatigue – often linked with depression and anxiety – is among its most debilitating manifestations. However, the associations between fatigue subtypes (physical vs mental), mental health symptoms, and acute disease severity on long-term health-related quality of life (HRQoL) remain unclear. This study examines the relationships between long COVID fatigue, depression, anxiety, acute disease severity, and HRQoL in a post-COVID-19 cohort. This prospective observational cohort study was conducted across 5 Portuguese hospitals between November 2020 and June 2022. Adults (≥18 years) with confirmed severe acute respiratory syndrome coronavirus 2 infection ≥6 months prior and fulfilling World Health Organization criteria for long COVID were included. Acute Coronavirus disease 2019 (COVID-19) severity was classified per World Health Organization definitions. The sampling strategy included patients across the severity spectrum. At 3 months postinfection (T1), patients received physician-led clinical assessments. At 6 months (T2), they attended in-person follow-up visits, completing standardized forms and validated questionnaires assessing post-acute sequelae. Fatigue was reported both binarily (yes/no) and via the chalder fatigue scale (11-item version). Anxiety and depression were assessed using the hospital anxiety and depression scale; post-traumatic stress disorder symptoms with the 14-item post-traumatic stress scale; and HRQoL with the EuroQol-5 dimensions. Descriptive statistics, analysis of variance, chi-square, and correlation analyses (Pearson’s or Spearman’s) were used to evaluate associations. Analyses were performed using SPSS (v27; IBM Corp., Amonk). Among 208 patients, fatigue was significantly associated with anxiety and depression ( P < .001). Physical fatigue correlated more strongly with depression ( r = 0.65, P < .001) and anxiety ( r = 0.58, P < .001) than mental fatigue ( r = 0.50 and R = 0.48, respectively; P < .001). Surprisingly, severe acute COVID-19 cases reported lower fatigue (CFQ: 13.3 ± 8.4) than mild (17.7 ± 7.2) or moderate (17.4 ± 8.0) cases ( P < .005), and higher HRQoL (EuroQol visual analog scale: 74.3 ± 20.3, P = .002). Anxiety symptoms were more common in mild cases ( P < .001); post-traumatic stress disorder symptoms did not differ by severity. Long COVID fatigue – especially physical – is strongly linked to depression and anxiety. Mild/moderate acute COVID-19 cases show greater fatigue and lower HRQoL than severe cases, highlighting the need for tailored long-term care regardless of initial severity.


  • Open Access

    A curious presentation of an endobronchial Hodgkin's lymphoma in a sarcoidosis-lymphoma syndrome

    by C. Barata, M.I. Pereira, M. Barbosa, F. Mousinho, J.P. Boléo-Tomé


  • Open Access

    Tobacco and COVID-19: A position from Sociedade Portuguesa de Pneumologia. Authors’ reply

    by C.P. Matos, J.P. Boléo-Tomé, P. Rosa, A. Morais


  • Open Access

    Tobacco and COVID-19: A position from Sociedade Portuguesa de Pneumologia

    by C.P. Matos, J.P. Boléo-Tomé, P. Rosa, A. Morais


  • Proteção Facial e Respiratória: Perspetivas Atuais no Contexto da Pandemia por COVID-19

    by David Peres, José Pedro Boléo-Tomé, Gilda Santos

    A nova pandemia por SARS-CoV-2 é um exemplo de uma emergência de saúde pública de âmbito internacional, associada a consideráveis desafios sociais e económicos. A nível das unidades de saúde há o risco que surtos nosocomiais sejam amplificadores locais. Perante tal, práticas de controlo de infeção são de importância crítica no funcionamento destes serviços, de que faz parte a utilização adequada de equipamento de proteção individual. Este deve ser adequado à via de transmissão do agente que, no caso do SARS-CoV-2, é através de gotícula e contacto. O indivíduo infetado, ao falar, tossir ou espirrar, dissemina gotículas que contêm o vírus, contaminando diretamente outros indivíduos, que estão num raio de um a dois metros, assim como o ambiente. A transmissão por via aérea também poderá ocorrer, no caso de procedimentos geradores de aerossóis. A nível da proteção respiratória existe, atualmente, fraca evidência que a utilização de respiradores permita maior proteção que máscara cirúrgica para o SARS-CoV-2 ou outros vírus(com exceção dos procedimentos geradores de aerossóis, em que a utilização de um respirador é recomendada). A proteção ocular deverá ser garantida sempre que houver risco de salpicos, gotículas ou aerossóis. A utilização incorreta de equipamento de proteção individual, para a via de transmissão do agente ou superior ao necessário, é uma forma de uso indevido e pode afetar o seu suprimento para as situações em que é realmente indicado. A disponibilização deste equipamento de proteção, e formação dos profissionais de saúde na sua correta utilização, é fortemente recomendado para garantir a prestação de cuidados seguros.


  • Open Access

    O Médico, o Doente Fumador e o Desafio dos Cigarros Eletrónicos

    by José Pedro Boléo-Tomé, Paula Pamplona, Paula Rosa, Carlos Robalo Cordeiro

    The Doctor, the Smoking Patient and the Challenge of Electronic Cigarettes


  • Open Access

    Breathe, breathe in the air, don’t be afraid to care

    by P. Pamplona, S. Ravara, J.P. Boléo-Tomé, P. Rosa, A. Morais


  • Open Access

    COPD and Cardiovascular Disease

    by S. André, B. Conde, E. Fragoso, J.P. Boléo-Tomé, V. Areias, J. Cardoso, On Behalf Of The Gi Dpoc-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica

    COPD is one of the major public health problems in people aged 40 years or above. It is currently the 4th leading cause of death in the world and projected to be the 3rd leading cause of death by 2020. COPD and cardiac comorbidities are frequently associated. They share common risk factors, pathophysiological processes, signs and symptoms, and act synergistically as negative prognostic factors. Cardiac disease includes a broad spectrum of entities with distinct pathophysiology, treatment and prognosis. From an epidemiological point of view, patients with COPD are particularly vulnerable to cardiac disease. Indeed, mortality due to cardiac disease in patients with moderate COPD is higher than mortality related to respiratory failure. Guidelines reinforce that the control of comorbidities in COPD has a clear benefit over the potential risk associated with the majority of the drugs utilized. On the other hand, the true survival benefits of aggressive treatment of cardiac disease and COPD in patients with both conditions have still not been clarified. Given their relevance in terms of prevalence and prognosis, we will focus in this paper on the management of COPD patients with ischemic coronary disease, heart failure and dysrhythmia.


  • Open Access

    Understanding COPD: A vision on phenotypes, comorbidities and treatment approach

    by E. Fragoso, S. André, J.P. Boleo-Tomé, V. Areias, J. Munhá, J. Cardoso, On Behalf Of Gi Dpoc-Grupo de Interesse na Doencça Pulmonar Obstrutiva Crónica

    Chronic Obstructive Pulmonary Disease (COPD) phenotypes have become increasingly recognized as important for grouping patients with similar presentation and/or behavior, within the heterogeneity of the disease. The primary aim of identifying phenotypes is to provide patients with the best health care possible, tailoring the therapeutic approach to each patient. However, the identification of specific phenotypes has been hindered by several factors such as which specific attributes are relevant, which discriminant features should be used for assigning patients to specific phenotypes, and how relevant are they to the therapeutic approach, prognostic and clinical outcome. Moreover, the definition of phenotype is still not consensual. Comorbidities, risk factors, modifiable risk factors and disease severity, although not phenotypes, have impact across all COPD phenotypes. Although there are some identified phenotypes that are fairly consensual, many others have been proposed, but currently lack validation. The on-going debate about which instruments and tests should be used in the identification and definition of phenotypes has contributed to this uncertainty. In this paper, the authors review present knowledge regarding COPD phenotyping, discuss the role of phenotypes and comorbidities on the severity of COPD, propose new phenotypes and suggest a phenotype-based pharmacological therapeutic approach. The authors conclude that a patient-tailored treatment approach, which takes into account each patient's specific attributes and specificities, should be pursued.